ArticleScientific reports2024

Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study.

Sijin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.